Mantell Associates has always had a primary focus on the CDMO space since the organisation was founded in 2019.
Recently, our CDMO business unit was split into Large Molecule and Small Molecule, to allow more time to generate new business and to hunt for the top talent that the industry has to offer. Over the past six months, there has been a lot of movement in the market of Small Molecule CDMO’s, particularly across companies that focus on APIs, Finished Dosage Forms and Chemical Markets, including the below…
David Enloe, Chief Executive Officer
Moved to: Recro
Moved from: Ajinomoto Bio-Pharma Services
Sector: Small Molecule CDMO
Having come from companies such as Lonza, Althea, Ajinomoto Bio-Pharma Servicesand Vivante GMP Solutions, David has joined an equally successful player within the CDMO space as President and CEO. Since joining Recro at the turn of this year, the company has boomed and seen an increase in sales, hires and stock. He brings to Recro 20 years executive leadership experience in biotechnology, GMP manufacturing, and clinical drug development, with a proven track record of building and growing CDMO businesses, forming strategic partnerships and leading global organisations.
Raymond De Vré, Chief Executive Officer
Moved to: PolyPeptide Group
Moved from: Dr. Reddy’s Laboratories
Sector: Small Molecule CDMO
Raymond joined PolyPeptide Groupas CEO at the beginning of Q2 this year, after serving as Senior Vice President, Head of Biologics at Dr. Reddy’swhere he had overall responsibility for the global business unit. Prior to his position at Dr. Reddy’s, Raymond was at McKinsey and Company for over 15 years, where he advised pharmaceutical, biotech and speciality chemical companies in Europe, the US and India. With more than two decades of industry experience, Raymond is a respected leader and will undoubtedly use his vast experience and skillset to contribute to PolyPeptide Group’s continued growth.
Patrick Walsh, Chief Executive Officer
Moved to: Alcami Corporation
Moved from: ANI Pharmaceuticals
Sector: Small Molecule CDMO
At the end of Q1, Patrick was appointed Chairman and Chief Executive Officer at Alcami, in addition to his Board Member responsibilities at various organisations. Throughout his career, Patrick has been CEO of multiple successful growth organisations and has served as Chairman, Non-Executive Chairman and on audit, nominating and compensation committees of private equity backed and publicly-traded corporations. He has considerable experience in corporate strategy, mergers and acquisitions, and creating high growth opportunities in the contract service, pharmaceutical or specialty pharma sectors.
Mark Chadwick, Chief Commercial Officer
Moved to: Charnwood Molecular
Moved from: Arcinova
Sector: Small Molecule CDMO
Mark is highly experienced at growing both discovery and development businesses, particularly in the biotech and pharmaceutical services sectors. He has recently joined the leadership team of Charnwood Molecular as CCO, leaving his previous position as CCO and SVP Business Development at Arcinova where he served for over five years. During his time at Arcinova, Mark and his team significantly expanded the customer base before the recent acquisition of Arcinova by Quotient Sciences. As well as this Mark has run many business units, focusing on the preclinical stage to phase II production.
Bob Muschert, Chief Commercial Officer
Moved to: Adare Pharma Solutions
Moved from: Lonza
Sector: Small Molecule CDMO
Adare Pharma Solutions have expanded their Executive Leadership team with the appointment of Bob as CCO, who makes the move over from Lonza. Prior to his time at Lonza, he held key leadership positions at the likes of Hovione, Pfizer and Merck. Bob has a consistent track record of delivering significant year on year cost savings by sourcing initiatives, contract negotiations, implementing operational improvement programs, and improving the Supply Chain. At Adare, Bob will be responsible for all global end to end commercial aspects, and will advance Adare’s leading position as a technology driven CDMO.
A NOTE FROM OUR CEO: Alessandro Mantell
It is with great pride and excitement that Mantell Associates have launched our first ever ‘Movers & Shakers’, which has been designed to highlight some of the biggest moves across the Life Science & Pharmaceutical Industry within the first six months of 2021.
Anyone who has followed the Mantell Associates journey so far will see the great extent of the effort and care that we have invested into making Mantell Associates not just ‘another recruitment business’ but a truly specialist, high-level headhunting organisation. We focus on Senior level appointments and consulting services, but we strive to share market intelligence and industry relevant content, and to provide exposure for individuals and businesses through the Mantell Associates Network podcast, which has already featured 21 industry leaders. In this ‘Movers & Shakers’ we look at the high level leadership moves between January and June this year, in particular across CDMO Large Molecule, CDMO Small Molecule, Life Sciences, Medical Devices & Consultancies, Market Access, HEOR. The incredible people and businesses that we highlight in this particular ‘Movers & Shakers’ are not only those who changed role but rather those who, during an incredibly difficult time, saw an opportunity to make an impact on the world and those around them.
Thank you from all of the Mantell Associates team – we hope you enjoy it!